Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 550 of 866 entries
View as:

Expanded Access to ABT-414

Phase: N/A Priority: Normal
NCT ID: NCT03123952 Org: User:
Start: - End: - Due: -

A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib

Phase: N/A Priority: Normal
NCT ID: NCT03823378 Org: User:
Start: 05/13/19 End: 09/09/20 Due: 09/09/21

Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Asthma

Phase: N/A Priority: Normal
NCT ID: NCT00986037 Org: User:
Start: 10/31/09 End: - Due: -

A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence

Phase: N/A Priority: Normal
NCT ID: NCT04949399 Org: User:
Start: 07/08/21 End: 12/20/22 Due: 12/20/23

Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04813263 Org: User:
Start: 05/28/21 End: 04/30/24 Due: 04/30/25

Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

Phase: N/A Priority: Normal
NCT ID: NCT04295538 Org: User:
Start: 09/06/20 End: 02/20/26 Due: 02/20/27

A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01897519 Org: User:
Start: 05/31/13 End: 05/31/14 Due: 05/31/15

Flexible-Dose Trial in Early Parkinson's Disease (PD)

Phase: N/A Priority: Normal
NCT ID: NCT04223193 Org: User:
Start: 01/06/20 End: 10/01/24 Due: 10/01/25

A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT05227690 Org: User:
Start: 06/30/22 End: 08/26/24 Due: 08/26/25

A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT06477926 Org: User:
Start: 07/09/24 End: 09/20/24 Due: 09/20/25

Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis

Phase: N/A Priority: Normal
NCT ID: NCT00797225 Org: User:
Start: 11/26/08 End: 02/24/10 Due: 02/24/11

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Phase: N/A Priority: Normal
NCT ID: NCT02219490 Org: User:
Start: 10/30/14 End: 05/13/21 Due: 05/13/22

Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection

Phase: N/A Priority: Normal
NCT ID: NCT03235349 Org: User:
Start: 09/29/17 End: 02/25/19 Due: 02/25/20

Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

Phase: N/A Priority: Normal
NCT ID: NCT04333576 Org: User:
Start: 08/10/20 End: 06/30/30 Due: 06/30/31

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

Phase: N/A Priority: Normal
NCT ID: NCT04888585 Org: User:
Start: 06/23/21 End: 08/04/23 Due: 08/04/24

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo

Phase: N/A Priority: Normal
NCT ID: NCT04927975 Org: User:
Start: 06/30/21 End: 08/29/23 Due: 08/29/24

A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment

Phase: N/A Priority: Normal
NCT ID: NCT02951117 Org: User:
Start: 08/31/17 End: 04/28/21 Due: 04/28/22

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02265731 Org: User:
Start: 09/22/14 End: 03/12/21 Due: 03/12/22

A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06158958 Org: User:
Start: 02/06/24 End: 01/20/28 Due: 01/20/29

Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment

Phase: N/A Priority: Normal
NCT ID: NCT02573740 Org: User:
Start: 12/31/15 End: 06/30/16 Due: 06/30/17

Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104

Phase: N/A Priority: Normal
NCT ID: NCT03413319 Org: User:
Start: 04/17/18 End: 11/20/19 Due: 11/20/20

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT02942290 Org: User:
Start: 01/12/17 End: 01/08/27 Due: 01/08/28

A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03105128 Org: User:
Start: 05/10/17 End: 04/14/21 Due: 04/14/22

A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)

Phase: N/A Priority: Normal
NCT ID: NCT03316794 Org: User:
Start: 01/04/18 End: 10/05/18 Due: 10/05/19

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT05443724 Org: User:
Start: 09/02/22 End: 02/28/26 Due: 02/28/27